Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
about
Ca2+ release from the endoplasmic reticulum of NY-ESO-1-specific T cells is modulated by the affinity of TCR and by the use of the CD8 coreceptor.RBP1L1, a retinoblastoma-binding protein-related gene encoding an antigenic epitope abundantly expressed in human carcinomas and normal testis.Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity.Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigenAutoantibodies to tumor-associated antigens in epithelial ovarian carcinoma.A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors.Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time.Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells.LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.Autoantibodies to tumor-associated antigens in breast carcinoma.NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability.Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytesTumor-specific shared antigenic peptides recognized by human T cells.Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.Antigen-specific immunotherapy and cancer vaccines.Specific roles of each TCR hemichain in generating functional chain-centric TCR.Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancerCytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses.Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myelomaInterplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasomeStructural and kinetic basis for heightened immunogenicity of T cell vaccines.Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patientsNY-ESO-1 immunotherapy for multiple myeloma.Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.Harnessing the immune system for ovarian cancer therapy.Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT.Functional role of T-cell receptor nanoclusters in signal initiation and antigen discriminationStrategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.Domain-swapped T cell receptors improve the safety of TCR gene therapy.Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization.Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses.
P2860
Q27646628-A238E34A-3785-434D-BF7A-09A398B12999Q30695952-9FD22243-3F30-499B-B58F-599111939C5BQ33239176-84023D4B-4560-40AC-8E24-173F00B89898Q33322422-B52098E2-97D9-450E-8D08-450658049F0EQ33633387-7B986FCE-F312-4949-A1B6-E19F5F816B1FQ33724878-CC01E738-E0EF-4E96-9A20-72CF751BCBB6Q33788685-5F284ED1-7EA4-4626-9C35-A83E7A5B75ACQ33821395-F10B2916-0396-4AF0-BC06-F886CD02333CQ33902421-BC64F9DD-87CF-436F-BFED-7F91CD937CD6Q34111719-14733F99-9799-4C0A-A761-DB59DCD7736CQ34339160-825F678A-03AE-48BA-9509-26AFE16B3449Q34388367-A82FE75B-3C2E-461B-B34D-D82B88087ABBQ34548080-B9B872E2-8F84-4785-A30A-2E05442ED82FQ34669820-E4319532-45E2-4708-846D-C0891603C2D6Q34706818-69809620-E104-4CEB-9CE7-12EEF38CC25AQ35005926-86200B7A-6889-40A7-A0A7-A1F984919AB9Q35005935-65858763-EB68-4F0C-A9AD-1DE3089D5E4BQ35005955-0D3C0B51-41E3-4611-B71E-C47DAAF07E49Q35199473-01238A3E-5850-40B8-8AFD-A483678AE890Q35205495-3B044572-AD14-4B11-9234-C19ED82F43EFQ35782660-69B145C1-E846-4D3E-ABEF-7F4516A35D17Q35848862-CFC25D4D-195A-4877-8079-D96ED67006EAQ35855820-250E49F1-CB31-4F98-95B7-718B146BD3F2Q35989451-48BE8190-7D9E-4EA7-AC1E-DE0B97A58976Q36080586-061B73D3-A491-4181-B117-0C614266E699Q36369920-7E36E560-9D07-449A-AEDA-EFB41565BB3AQ36403443-3FCF8BD7-17A7-4F10-A876-FE2265B3DCE1Q36471827-6DE971DE-A006-40A5-B52B-207585F80E29Q36551911-400795DE-4E74-4BE7-9377-F92F29E97732Q36637651-4D46DBD1-590A-4BD5-B1D2-887A08120BE2Q36759301-B9B10B0A-C8E4-4161-9A03-F5D0AB80644AQ37043688-6A49DF5A-EEA0-4C45-A509-EC18435828C8Q37107843-86741BE8-9CF2-4935-85F6-A7A5AAFE8E9CQ37145706-0AE0F7CA-8213-4E72-BCD4-457A1DBF6CAFQ37264253-2600B64E-5408-4791-8DA7-E85E54ACBCB2Q37266210-7C2C0207-4BB3-4F57-AE8D-D0E63539F0EFQ37401728-6F1FD66C-2FB0-4ED5-9CDE-C01DAFC9F8A0Q37513109-76119E29-4A10-4905-A27C-5929B3D9B792Q37679220-103A3AEC-6172-414A-B610-2B8B0B6CBFE4Q37729146-7859E5E5-2BAA-48A0-8D3B-C205ABD740F3
P2860
Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Identification of NY-ESO-1 pep ...... ulation of tumor-reactive CTL.
@en
type
label
Identification of NY-ESO-1 pep ...... ulation of tumor-reactive CTL.
@en
prefLabel
Identification of NY-ESO-1 pep ...... ulation of tumor-reactive CTL.
@en
P2093
P1476
Identification of NY-ESO-1 pep ...... ulation of tumor-reactive CTL.
@en
P2093
Cerundolo V
P304
P356
10.4049/JIMMUNOL.165.2.948
P407
P577
2000-07-01T00:00:00Z